Bar-Natan, Michal

Publications

Sort by

Co-Author Network

selected publications

'Secondary' acute lymphoblastic/lymphocytic leukemia - done playing second fiddle?. Blood reviews. 2023 Review GET IT
Times cited: 5
Immunoglobulin repletion during blinatumomab therapy does not reduce the rate of secondary hypogammaglobulinemia and associated infectious risk. Blood research. 2022 Academic Article GET IT
Times cited: 9
PD-1 inhibition in advanced myeloproliferative neoplasms. Blood advances. 2021 Academic Article GET IT
Times cited: 28
Multimodal single-cell analysis of cutaneous T-cell lymphoma reveals distinct subclonal tissue-dependent signatures. Blood. 2021 Academic Article GET IT
Times cited: 53
Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies. HemaSphere. 2021 Academic Article GET IT
Times cited: 38
Developing strategies to reduce the duration of therapy for patients with myeloproliferative neoplasms. Expert review of hematology. 2020 Academic Article GET IT
Times cited: 2
Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia. Journal of hematology & oncology. 2020 Letter GET IT
Times cited: 54
Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm. Leukemia research. 2020 Letter GET IT
Times cited: 21
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. The Lancet. Haematology. 2020 Information Resource GET IT
Times cited: 55
JAKs to STATs: A tantalizing therapeutic target in acute myeloid leukemia. Blood reviews. 2019 Review GET IT
Times cited: 40
Low SATB1 Expression Promotes IL-5 and IL-9 Expression in Sézary Syndrome. The Journal of investigative dermatology. 2019 Letter GET IT
Times cited: 8
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia. 2019 Academic Article GET IT
Times cited: 200
New insights into the causes of thrombotic events in patients with myeloproliferative neoplasms raise the possibility of novel therapeutic approaches. Haematologica. 2019 Editorial Article GET IT
Times cited: 16
Management of Intraoperative Coagulopathy. Neurosurgery clinics of North America. 2018 Review GET IT
Times cited: 8
MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism. Journal of cellular and molecular medicine. 2018 Academic Article GET IT
Times cited: 15
MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs. Leukemia. 2017 Academic Article GET IT
Times cited: 64
Extended Small-Dose Platelet Transfusions in Multitransfused Hemato-Oncological Patients: A Single-Center Experience. Acta haematologica. 2017 Academic Article GET IT
Times cited: 4
Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1. British journal of haematology. 2017 Academic Article GET IT
Times cited: 28
Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. Blood. 2016 Academic Article GET IT
Times cited: 93
Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. Blood. 2015 Academic Article GET IT
Times cited: 32
High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?. Hematological oncology. 2015 Academic Article GET IT
Times cited: 12
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014 Academic Article GET IT
Times cited: 508
Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hemato-oncological patients: randomized controlled trial. American journal of hematology. 2014 Academic Article GET IT
Times cited: 17
NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML. Blood. 2014 Academic Article GET IT
Times cited: 43
Immunotherapy for multiple myeloma. Expert review of hematology. 2014 Review GET IT
Times cited: 12
A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 86
Alternative splicing in chronic myeloid leukemia (CML): a novel therapeutic target?. Current cancer drug targets. 2013 Review GET IT
Times cited: 10
Early death in patients diagnosed with non-Hodgkin's lymphoma. Annals of hematology. 2012 Academic Article GET IT
Times cited: 13
The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations. Genes & cancer. 2012 Academic Article GET IT
Times cited: 89
STAT signaling in the pathogenesis and treatment of myeloid malignancies. JAK-STAT. 2012 Review GET IT
Times cited: 171
Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cells. Leukemia. 2011 Letter GET IT
Times cited: 36
The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011 Academic Article GET IT
Times cited: 241
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America. 2009 Academic Article GET IT
Times cited: 297
Epstein-Barr virus-associated post-transplant lymphoproliferative disorder. The Israel Medical Association journal : IMAJ. 2006 Editorial Article GET IT
Times cited: 7
Confirmation of the association between male pattern baldness and the androgen receptor gene. European journal of dermatology : EJD. 2005 Academic Article GET IT
Times cited: 54
Sternoclavicular infectious arthritis in previously healthy adults. Seminars in arthritis and rheumatism. 2002 Review GET IT
Times cited: 63

more ...

less ...

Background

education and training

B.Med.Sc., Sackler School of Medicine, Tel Aviv University (Israel) 1999
M.D., Sackler School of Medicine, Tel Aviv University (Israel) 1999

Contact

full name

Michal Bar-Natan

primary email

jcf9015@med.cornell.edu

webpage

Clinical Profile

VIVO Weill Cornell Medical College

Michal Bar-Natan Associate Professor of Clinical Medicine

Publications

selected publications

Background

education and training

Contact

full name

primary email

webpage

Phone

Publications

selected publications

Background

education and training

Contact

full name

primary email

webpage